Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-N-Allyl-arginine is a synthetic derivative of the amino acid arginine in which an allyl group is attached to the nitrogen at position 5. It acts as a competitive and reversible inhibitor of neuronal nitric oxide synthase (nNOS), also known as nitric oxide synthase 1. By inhibiting nNOS activity, it reduces the production of nitric oxide from L‑arginine in neuronal tissues. This compound has been used experimentally to study the role of nNOS in various physiological and pathological processes but is not approved for clinical use[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-N-allyl-arginine.